To evaluate the efficacy and safety of nabuliumab combined with ipilimumab in the first-line treatment of locally advanced lung adenocarcinoma.
Ninety-two patients with locally advanced lung adenocarcinoma were randomly divided into control group and combined group by random number table method, 46 cases in each group. The control group received pemetrexed combined with cisplatin, and the combined group received nabuliumab combined with ipilimumab. Disease control rate (DCR), objective response rate (ORR), safety, tumor downstaging rate, major pathological response (MPR), pathological complete response (pCR) rate and tumor markers were compared between the two groups.
The rates of ORR, DCR, tumor downstaging in the combined group were higher than those in the control group (P<0.05), and the incidence of adverse reaction in grade Ⅲ and above was lower than that in the control group (P<0.05). After 2 months of treatment, serum carcino-embryonic antigen (CEA), cytokeratin 19 fragment antigen 21-1 (Cyfra21-1) and neurone-specific enolase (NSE) levels in 2 groups were decreased compared with those before treatment (P<0.05), and serum CEA, Cyfra21-1 and NSE levels in combined group were significantly lower than those in control group (P<0.05).
Nabuliumab combined with ipilimumab in the first-line treatment of locally advanced lung adenocarcinoma can increase ORR, DCR, tumor descending stage rate, and the adverse reactions are controllable.
| 科 Family | 属数 Number of genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) | 属 Genus | 种数 Number of species | 占总种数比例 Percentage of total species (%) |
|---|---|---|---|---|---|---|
| 鹅膏菌科Amanitaceae | 2 | 11 | 5.26 | 鹅膏菌属 Amanita | 10 | 4.78 |
| 小菇科 Mycenaceae | 2 | 12 | 5.74 | 丝盖伞属 Inocybe | 5 | 2.39 |
| 多孔菌科 Polyporaceae | 8 | 14 | 6.70 | 蜡蘑属 Laccaria | 5 | 2.39 |
| 红菇科 Russulaceae | 3 | 23 | 11.00 | 小皮伞属 Marasmius | 6 | 2.87 |
| 小菇属 Mycena | 11 | 5.26 | ||||
| 光柄菇属 Pluteus | 5 | 2.39 | ||||
| 红菇属 Russula | 17 | 8.13 | ||||
| 栓菌属 Trametes | 5 | 2.39 |